Genmab — Maj 2024
-
Data fra et større studie med Pembrolizumab og Chemo i NSCLC. Meget dårlig 5 års prognose. https://ascopubs.org/doi/10.1200/JCO.22.01990 Så må vi se frem til yderligere data på 1042.
-
Epcoritamab and Rybrevant on the EMA agenda this week. Also Tisotumab on Initial applications; List of questions (Day 120; Day 90 for
procedures with accelerated assessment timetable); so i guess that means they got accelerated assessment? (as the applicatoin was validated in Feb) https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-27-30-may-2024_en.pdf -
at least someone has epco in their list of top ASCO abstracts
- Hematologic Malignancies ASCO 2024 Preview - https://www.delveinsight.com/asco-conference/article/hematologic-malignancies-preview-asco-2024?utm_source=asco&utm_medium=promotion&utm_campaign=kpr -
Acasunlimab starting on the EMEA treadmill on the Paediatric Committee (PDCO)
Agenda https://www.ema.europa.eu/en/documents/agenda/agenda-pdco-agenda-28-31-may-2024-meeting_en.pdf -
Nummer 10 hvis man fraregner covid
-
Nummer 3 er en anden dansker. Ozempic. Den når meget tæt på 1. pladsen i år. Næste år meget klar 1. plads med den første non covid til at runde $30 mia og $40 mia
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind